Status:

COMPLETED

Safety of BBB Opening With the SonoCloud

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Glioblastoma

Glioma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

PURPOSE: The purpose of this study is to determine whether transient opening of the blood-brain barrier by pulsed ultrasound using the SonoCloud implantable ultrasound device is safely tolerated in pa...

Detailed Description

For patients with recurrent malignant gliomas, who have already been treated by a combination of surgery, radiation therapy and/or chemotherapy, few treatment options currently exist. Salvage therapie...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Age greater than 18 years.
  • Subjects with recurrent glioma who have failed standard therapy with surgery and/or treatment with radiation and temozolomide.
  • Patient eligible for Carboplatin-based chemotherapy
  • Contrast-enhanced tumor less than 35 mm in diameter
  • No risk of cerebral herniation
  • Able to tolerate pre/post procedure steroid treatment
  • Social security affiliated (in France)
  • Able and willing to give signed and informed consent
  • Normal biological status
  • Hemoglobin ≥ 10 g/dl
  • Platelets ≥ 100000/mm3
  • Neutrophils ≥ 1500/mm3
  • Normal creatine clearance ≥ 60ml/mn
  • ASAT \< 3 N
  • ALAT \< 3 N
  • Normal Bilirubin Level \< 1.5 N
  • Alkaline Phosphatase \< 3 N
  • INR \< 1.5
  • Prothrombin Level ≥ 70%
  • Exclusion criteria:
  • Allergic to Iodine, Gadolinium, Xylocain
  • Contra-indications to echographic contrast agent (microbubbles)
  • Severe Renal insufficiency
  • Hepatic insufficiency
  • Possible toxic treatment for CNS
  • Previously infected surgical field
  • Uncontrolled epilepsy
  • MRI contra-indications
  • Hemostasis troubles thrombopenia \<75.000, TP \<60%, INR \>1.5, anti-platelet or anticoagulant therapy on-going)
  • Active phlebitis or active pulmonary embolism
  • Pregnant or currently breast-feeding
  • Patients under judicial protection

Exclusion

    Key Trial Info

    Start Date :

    July 1 2014

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    July 1 2018

    Estimated Enrollment :

    27 Patients enrolled

    Trial Details

    Trial ID

    NCT02253212

    Start Date

    July 1 2014

    End Date

    July 1 2018

    Last Update

    October 12 2018

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Groupe Hospitalier Pitié Salpetriere - Neurosurgery Department

    Paris, France, 75013